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To evaluate proteins associated with the development of diabetic nephropathy, a major cause of the end-stage renal disease,
we analyzed protein expression in isolated glomeruli from spontaneous type 2 diabetic (OLETF) rats and their age-matched
control littermates (LETO) in the early and proteinuric stages of diabetic nephropathy using QSTAR Elite LC-MS/MS. Among
the 191 and 218 proteins that were altered signiﬁcantly in the OLETF rats, twenty-four were actin cytoskeleton-associated proteins
implicated in the formation of stress ﬁbers, and the impairment of actin polymerization, intermediate ﬁlaments and microtubules.
Importantly, sorbin and SH3 domain containing 2 (SORBS2), which is involved in the formation of stress ﬁbers, was signiﬁcantly
upregulated in both stages of diabetic nephropathy (1.49- and 1.97-fold, resp.). Immunohistochemical and quantitative-PCR
analyses revealed upregulation of SORBS2 in podocytes of glomeruli of OLETF rats. Our ﬁndings suggested that SORBS2 may
be associated with the development of diabetic nephropathy possibility by reorganization of actin ﬁlaments.
1.Introduction
Diabetes mellitus accounts for more cases of end-stage renal
disease than any other cause of chronic kidney disease [1].
While glomerular hypertrophy, mesangial matrix expansion,
and glomerular basement membrane (GBM) thickening are
the classical hallmarks of diabetic glomerular lesions, studies
of diabetic patients and animal models have revealed that the
onset of proteinuria is most closely associated with podocy-
topathies, such as podocyte apoptosis, hypertrophy, detach-
ment from the GBM, and foot process eﬀacement [2]. In-
deed, diabetic nephropathy is now recognized as one of the
major podocyte-associated diseases [3]. The podocyte is an
excellent model system for studying actin cytoskeleton dy-
namics in a physiological context because changes in actin
dynamics transfer directly into changes of kidney function
[4]. Previous investigations have shown that the cytoskeleton
on the GBM side in podocytes during foot process eﬀace-
ment is comprised of highly-ordered, actin-based bundles
that run parallel to the longitudinal axis of the foot processes
[4] and that actin ﬁbers gather to form the stress ﬁbers
[4, 5]. Therefore, reorganization of the actin ﬁlaments is
indispensable for foot process eﬀacement.
Sorbin and SH3 domain containing 2 (SORBS2), alpha-
actinin 1 (ACTN1), alpha-actinin 4 (ACTN4) and Rho GDP
dissociationinhibitoralpha(ARHDGDIA)areproteinsasso-
ciated with stress ﬁber formation [6–11]. The relationship
between these proteins and diabetic nephropathy has not
been elucidated, although some of these proteins have been
reported to be important in stress ﬁber formation in pod-
ocytopathies or proteinuria [4, 8, 9, 12]. The underlying
cytoskeletal components that initiate and regulate the dy-
namic changes of these foot processes remain unclear.2 Experimental Diabetes Research
Recently, proteome analysis has increasingly been used
in the discovery of disease-speciﬁc proteins and biomarkers
of kidney diseases [13, 14]. Proteome analysis of diabetic
glomeruli from renal biopsy specimens of diabetic patients is
diﬃcult, due to the fact that renal biopsy is clinically limited
in diabetic patients, and only small (often insuﬃcient) quan-
tities of glomeruli can be obtained from renal biopsy speci-
mens. From these concerns, in order to reveal which proteins
are involved in the diabetic glomerular alterations, including
podocytopathies, we conducted a proteome analysis of iso-
lated glomeruli from spontaneous type 2 diabetic (Otsuka
Long-Evans Tokushima Fatty (OLETF)) rats and their age-
matched control littermates (Long-Evans Tokushima Lean
(LETO)) rats at 27 (early stage of diabetic nephropathy)
and 38 (proteinuric stage of diabetic nephropathy) weeks of
age using QSTAR Elite liquid chromatography with tandem
mass spectrometry (QSTAR Elite LC-MS/MS) and iTRAQ
technology.
2.MaterialsandMethods
2.1. Animals. All experimental procedures were conducted
after obtaining approval of the Animal Care and Use Com-
mittee of the Osaka City University Medical School and in
accordance with the Guide for Laboratory Animals. OLETF
and LETO rats (n = 20, resp.) were provided by Otsuka
Pharmacology Co., Ltd. (Tokushima, Japan). The diabetic
phenotype of the OLETF rat has been extensively evaluated:
(i) 25-week-old rats develop diabetes (hyperglycemia, hyper-
lipidemia, etc.) at nearly 100% incidence and (ii) 30-week-
oldratsdevelopproteinuria[15].Therefore,weassumedthat
OLETF rats develop diabetic nephropathy with the early and
the proteinuric stages at 27 and 38 weeks of age, respectively.
10 OLETF rats and 10 LETO rats were used for analysis at
eachtimepoint.Allanimalswerehousedindividuallyineach
cage in an animal facility maintained on a 12-h (7:00–19:00)
light/dark cycle, at a constant temperature of 23 ± 1◦Ca n d
relativehumidityof44±5%for21and32weeks,respectively,
fromthestartoftheexperiment andwereprovidedtapwater
and food (rodent pellet diet MF 348kcal/100g, containing
4.2% crude fat; Oriental Yeast Co., Tokyo, Japan) ad libitum.
2.2.BiochemicalCharacterization. Totalcholesterolandcrea-
tinine in serum specimens (n = 10/group), hemoglobin A1c,
fasting plasma glucose concentrations in plasma specimens
(n = 10/group), and protein and creatinine concentrations
in spot urine samples (n = 5/group) were measured using
an autoanalyser (Mitsubishi Chemical Medience Co., Ltd.,
Osaka, Japan).
2.3. Histopathological Examination. Renal tissues were ﬁxed
in 10% neutral formalin solution, embedded in paraﬃn, and
cut into 3μm sections using conventional techniques. Sec-
tions were stained with hematoxylin and eosin and periodic
acid-Schiﬀ (PAS) reagent and examined histopathologically
by light microscopy.
2.4. Glomerular Isolation. Rats were anesthetized with in-
traperitoneal injection of pentobarbital (60mg/kg) for
euthanasia and necropsy. After laparotomy, the kidneys were
perfused with ice-cold phosphate-buﬀered saline (PBS) until
they were blanched. Glomeruli were isolated by a sieving
technique, as described previously [16, 17]. Isolated glomer-
uli were collected under an inverted microscope to minimize
tubular contamination (less than 5% tubular fragments) and
centrifuged at 453g for 10min. The pellets were collected
and used for proteome analysis.
2.5. Lysis and Digestion, iTRAQ Labeling, and LC-ESI MS/MS
Analysis. The lyophilized samples were dissolved in 1000μL
tissue protein extraction reagent lysis buﬀer (Pierce, IL,
USA) with protease inhibitor (p8340, Sigma-Aldrich). The
glomerularlysateswereultrasonicatedandinsolublematerial
was removed by centrifugation at 13,000g for 15min at
10◦C. Protein concentrations were quantiﬁed using the BCA
Protein Assay kit (Pierce, Ill, USA). Protein reduction, al-
kylation, digestion and subsequent peptide labeling were
performed using the AB Sciex iTRAQ Reagent Multi-Plex Kit
(AB Sciex, Foster City, Calif, USA) according to the man-
ufacturer’s instructions with minor modiﬁcations [18, 19].
Brieﬂy, 50μg samples of protein were incubated at 60◦Cf o r
60min in 20μL dissolution buﬀer (0.5M triethylammonium
bicarbonate, 0.2% SDS) with 2μL reducing reagent (50mM
tris(2-carboxy-ethyl)phosphine). Free cysteine sulfhydryl
groups were blocked by incubation with 1μL cysteine
blocking reagent (20mM methyl methanthiosulfonate) at
roomtemperaturefor10min.TenμLoftrypsinsolution(AB
Sciex, Foster City, Calif, USA) was added, and each sample
was incubated overnight at 37◦C. Samples from OLETF and
LETO rats were labeled with iTRAQ114 and iTRAQ115, re-
spectively, and then mixed into one tube and fractionated
using six concentrations of KCl solutions (10, 50, 70, 100,
200, and 350mM) on an ICAT cation exchange cartridge
(AB Sciex, Foster City, Calif, USA). After desalting and
concentrating, peptides in each fraction were quantiﬁed by a
DiNa-AI nano LC System (KYA Technologies, Tokyo, Japan)
coupled to a QSTAR Elite Hybrid MS/MS spectrometer
through a Nanospray ion source (AB Sciex, Foster City, Calif,
USA), as described previously [19].
2.6. Identiﬁcation of Proteins by IPA. Protein Pilot 2.0 soft-
ware with the Paragon Algorithm (AB Sciex, Foster City,
Calif, USA) was used for the identiﬁcation and relative quan-
tiﬁcation of proteins. Tandem mass spectrometry data were
compared against the rat protein database from Swiss-Prot
57.4 (20,400 sequences). We report only protein identiﬁca-
tionswith>95%statisticalconﬁdenceintheProteinPilot2.0
software.
The Ingenuity Analysis (IPA; Ingenuity Systems, Moun-
tain View, Calif, USA) was utilized to identify networks of
interacting proteins, functional groups, and pathways. Infor-
mationregardingthefunctionandcellularlocalizationofthe
identiﬁed proteins was obtained from IPA.
2.7. Immunohistochemistry for SORBS2. Immunohisto-
chemical staining of the kidney sections was performed
according to the avidin-biotin complex method, as describedExperimental Diabetes Research 3
previously [20], using primary mouse monoclonal anti-rat
SORBS2 (clone S5C, Sigma-Aldrich), After deparaﬃnization
with xylene and gradual dehydration, antigen retrieval was
undertaken by microwaving in sodium citrate buﬀer (pH 6)
for 25min and endogenous peroxidase activity was blocked
by 3% hydrogen peroxide for 5min. Sections were incubated
with 1.5% normal horse or goat serum in PBS for 15min
and then with diluted primary antibody (1:500), overnight
at 4◦C. Biotinylated horse anti-mouse antibodies (diluted
1:200) were applied as the secondary antibodies for 30min,
and the slides were then incubated with the avidin-biotin
peroxidase complex for 30min. The peroxidase reaction
was developed using 0.02∼0.033% 3,3-diaminobenzidine
tetrahydrochloride (DAB) and 0.03% hydrogen peroxide in
tris-buﬀered saline for 1–5min. Hematoxylin was used for
counterstaining.
2.8. Immunoﬂuorescence for SORBS2 and Synaptopodin.
Double immunoﬂuorescence of SPRBS2 and synaptopodin,
a podocyte marker proteins was performed as previously
described [21–23]. Four-μm-thick frozen kidney tissue sec-
t i o n sw e r eﬁ x e dw i t hi c e - c o l da c e t o n ea t−20◦C for 5min,
followed by permeabilization with 1% Tween 20PBS for
5min at room temperature. After rinsing with 1% Tween
20PBS, unspeciﬁc binding sites were blocked with horse
anti-mouse and goat anti-rabbit serum in PBS for at
least 30min. Primary antibodies (prediluted in blocking
solution) for SORBS2 (1:250) and synaptopodin (clone ab
101883, Abcam) (1:300) were applied for 60min at room
temperature, followed by incubation with the secondary an-
tibody ﬂuorescein red-conjugated horse anti-mouse IgG
(Alexa Fluor 594) (Life technologies, Calif, USA) and ﬂuo-
rescein green-conjugated goat anti-rabbit IgG (Alexa Fluor
488) (Life technologies, Calif, USA) for 30 minutes at room
temperature. Spatial colocalization of SORBS2 immunore-
activity (red ﬂuorescence) with synaptopodin (green ﬂu-
orescence), resulting in yellow, was obtained by overlay-
ing separately recorded images on a color image. The
immunoﬂuorescence was analyzed by confocal microscopy
with the help of the Fluoview software (Olympus Optical,
Tokyo, Japan).
2.9. Validation of SORBS2 mRNA Expression by Real-Time
Quantitative PCR (Q-PCR)
2.9.1. RNA Preparation. Glomeruli from OLETF and LETO
rats at the proteinuric stage (n = 3, resp.) were laser-mi-
crodissected using the ZEISS PALM MB4 Microdissection
System (ZEISS, Munich, Germany), according to the man-
ufacturer’s instructions. Total RNA was isolated from glom-
eruliusing4Mguanidinethiocyanate,25mMsodiumcitrate
with 0.5% sarkosyl buﬀer with the phenol-chloroform-
isoamyl alcohol extraction method, using glycogen as a
carrier, as described previously [24]. Reverse transcription of
total RNA was performed with Oligo-dT primer, and cDNA
samples were stored at −20◦C until assayed.
2.9.2. Real-Time Q-PCR. PCR amplicons were used to
conﬁrm SORBS2 gene expression using real-time Q-PCR.
Primer sequences were designed with the Primer Express
software (Applied Biosystems, USA). The probes and
primers were as follows: TaqMan probe and primer set
Rn00587190 m1 for SORBS2 (NM 053770.1) and TaqMan
probe 5 -TGA GAC CTT CAA CAC CCC AGC CAT G-3 ,
and primers: forward 5 -TCA AAT AAG CCA CAG CGT
C-3 , reverse 5 -AAC CAG CCG TCAT CACA C-3  for
GAPDH,cytoplasmic(NM 017008.3).ThecDNAgenerated
from each sample was used for Q-PCR according to the
manufacturer’s instructions, with GAPDH as an internal
control.
2.10. Ultrastructural Examination. Separate portions of the
kidneys from the OLETF and LETO rats (n = 5, resp.) at
38 weeks of age were also prepared for electron microscopy.
Specimens were obtained from the renal cortex, ﬁxed in
0.1M cacodylate buﬀer solution (pH 7.4) containing 3%
glutaraldehyde, and postﬁxed in the same buﬀer containing
1% osmium tetroxide at 4◦C, as previously described [25].
Seventy nm sections were stained with uranyl acetate and
lead citrate for examination using a JEM 1200 EXII electron
microscope (JEOL, Tokyo, Japan).
2.11. Statistical Analysis. Statistical calculations were per-
formed using Graph-Pad Prism version 5.0 for Windows
(Graphpad Software, San Diego, Calif). For normally dis-
tributeddata,statisticalsigniﬁcance(P<0.05)wasevaluated
using the unpaired t-test followed by an analysis of variance
(F-test). In the case of statistically signiﬁcant diﬀerences re-
garding variances, the Welch test was used to conﬁrm the
diﬀerences between groups. For nonparametric testing, the
Mann-Whitney U-test was applied. The results are presented
asboxplots/dotplots.Allvaluesareexpressedasthemeans ±
SD.Foranalysisofproteinexpression,statisticalanalysiswith
Protein Pilot 2.0 software was employed.
3. Results
3.1. General Observations. The OLETF rats exhibited pol-
yphagia and obesity from the very early stages of life. At 27
weeks of age (early stage of diabetic nephropathy), the mean
bodyweightoftheOLETFrats(642±40.9g)wassigniﬁcantly
higher than that of the LETO rats (491 ± 34.6g). At 38
weeks of age (proteinuric stage of diabetic nephropathy), the
body weights of the LETO rats were increased, although the
ﬁnal values for the OLETF (621 ± 69.4g) and the LETO
(580 ± 80.7g) rats were not signiﬁcantly diﬀerent. At both
time points, the kidney-to-body weight ratio of the OLETF
rats (27 weeks: 0.703% ±0.10%, 38 weeks: 0.780% ±0.12%)
wassigniﬁcantlyhigherthanthatoftheLETOrats(0.597%±
0.054% and 0.592% ±0.050%, resp.).
The mean blood glucose, hemoglobin A1c and total
cholesterol levels in the OLETF rats (27 weeks: 183 ±
58.9mg/dL,4.4 ±0.85%, 123 ±23.1mg/dL, 38 weeks: 248 ±
53.6mg/dL,5.7%±1.2%, and 153±34.6mg/dL,resp.)were
increased signiﬁcantly compared with those in the LETO
rats (27 weeks: 135 ± 34.2mg/dL, 3.3% ± 0.11%, 97.4 ±
9.5mg/dL, 38 weeks: 129 ± 25.3mg/dL,3.3% ± 0.18%, and
101 ± 9.37mg/dL, resp.). The serum creatinine levels were4 Experimental Diabetes Research
Table 1: Biological parameters from OLETF and LETO rats at 27 and 38 weeks of age.
OLETF
(n = 10)
LETO
(n = 10) P value OLETF
(n = 10)
LETO
(n = 10) P value
27 weeks 38 weeks
Body weight (g) 642 ±40.9 491 ±34.6 <0.0001 621 ±69.4 580 ±80.7 0.2089
Food intake (g/day) 34.9 ±6.11 9 .1 ±1.5 <0.0001 39.3 ±6.12 9 .7 ± 2.0 <0.0001
Kidney-to-body weight ratio (%) 0.703 ±0.10 0.597 ±0.054 0.0091 0.780 ±0.12 0.592 ±0.050 0.0008
Fasting plasma glucose (mg/dL) 183 ±58.9 135 ±34.2 00388 248 ±53.6 129 ±25.3 <0.0001
Hemoglobin A1c (%) 4.4 ±0.85 3.3 ±0.11 0.0021 5.7 ±1.23 .3 ±0.18 0.0001
Total cholesterol (mg/dL) 123 ±23.19 7 .4 ±9.5 0.0081 153 ±34.6 101 ±9.37 0.0009
Creatinine (mg/dL) 0.24 ±0.04 0.36 ±0.04 <0.0001 0.33 ±0.05 0.46 ± 0.1 0.0031
Urinary protein-to-creatinine
ratio (mg/mg)
2.73 ±2.10
(n = 5)
∗
0.60 ±0.08
(n = 5)
∗ <0.0001 5.65 ±2.36
(n = 5)
∗
0.94 ±0.38
(n = 5)
∗ <0.0001
Values are expressed as the mean ± SD.
∗Urinary specimens were obtained from 5 rats per group to measure urinary protein and creatinine levels.
OLETF: Otsuka Long-Evans Tokushima Fatty, LETO: Long-Evans Tokushima Lean.
signiﬁcantlyhigheratbothnephropathystagesforLETOrats
(27 weeks: 0.36 ± 0.04mg/dL and 38 weeks: 0.46 ± 0.10mg/
dL) compared with the OLETE rats (0.24 ± 0.04mg/dL and
0.33 ± 0.05mg/dL). The urinary protein to creatinine ratio
in the OLETF rats was also elevated signiﬁcantly at both
time points examined (27 weeks: 2.73 ± 2.10mg/mg and 38
weeks: 5.65 ± 2.36mg/mg) compared with the LETO rats
(0.60 ±0.08mg/mg and 0.94 ±0.38mg/mg) (Table 1).
3.2. Histopathological Examination. In the OLETF rats,
histopathological examination demonstrated both focal and
segmental glomerular changes. Slight expansion of the me-
sangialmatrix wasobserved withmesangial cellproliferation
at 27 weeks of age (Figure 1(a)). At 38 weeks of age, in ad-
dition to the mesangial area, a few glomeruli exhibited
segmental lesions with PAS-positive deposits in the mesang-
ium or capillary that resembled the ﬁbrin caps commonly
observed in exudative lesions in human diabetic nephropa-
thy (Figure 1(c)). In the LETO rats, there were no obvious
histopathological changes at both time points (Figures 1(b)
and 1(d)).
3.3. Alterations of Protein Expression in Glomeruli from Dia-
betic Rats. The results of QSTAR Elite LC-MS/MS and Pro-
teinPilotanalysesaresummarizedinTable2.Alteredexpres-
sion of 191 (91 up- and 100 downregulated) and 218 (121
up- and 97 downregulated) proteins was observed in isolated
glomeruli from OLETF rats at the early and proteinuric
stages of diabetic nephropathy, respectively. These proteins
were involved in glycolysis, oxidative stress, and podocyte
injury, based upon the IPA ﬁndings (Figure 2).
Eighty-seven proteins were diﬀerentially expressed in
isolated glomeruli from OLETF rats compared with those
from LETO rats at both stages of diabetic nephropathy.
Among these 87 proteins, 24 were involved in actin cyto-
skeleton reorganization, that is, formation of stress ﬁbers
(SORBS2, ACTN1, ACTN4 and ARHGDIA), polymeriza-
tion of actin ﬁlaments (actin-related protein 2/3 complex
subunit 1 beta (ARPC1B), actin-related protein 2/3 com-
plex subunit 5 (ARPC5), actin-related protein 3 homolog
(ACTR3), myristoylated alanine rich kinase C substrate
(MARCKS), and adducin 1 alpha (ADD1)), microtubules
(tubulin alpha 1c (TUBA1C) and dynein cytoplasmic 1
(DYNC1)) intermediate ﬁlaments (vimentin (VIM), lamin
A/C (LMNA), desmin (DES), nestin (NES) and plectin1
(PLEC1)), formation of GBM (integrin beta 1 (INTGB1),
vinculin (VCL) and agrin (AGRN)), and other actin-binding
proteins (plastin 3 (PLS3), spectrin alpha non-erythrocytic
1 (SPTAN1), calponin 3 (CNN3), tropomyosin 3 (TPM3)
andezrin(EZR)).Amongtheseproteins,Table2presentsthe
actin cytoskeleton-associated proteins with high- or low-fold
changes of more than 20% (average iTRAQ ratio >1.20 or
<0.83) and P values less than 0.05. SORBS2 was the only up-
regulated protein in glomeruli from OLETF rats at both the
early and the proteinuric stages of diabetic nephropathy.
3.4. Conﬁrmation of SORBS2 Expression by Immunohisto-
chemistry. Figures 1(e), 1(f), 1(g), and 1(h) show represen-
tative immunostaining results for the SORBS2. There were
no clear diﬀerences in the expression of SORBS2 between the
OLETF and LETO rats at 27 weeks of age (Figures 1(e) and
1(f)). However, SORBS2 was clearly observed in podocytes
from OLETF rats at 38 weeks of age (Figures 1(g) and 1(h)).
Immunoﬂuorescence of SPRBS2 and synaptopodin are
shown in Figure 3. SORBS2 was observed in glomeruli from
O L E T Fr a t sa t3 8w e e k so fa g e( F i g u r e3(a)). Synaptopodin
w a so b s e r v e di ng l o m e r u l if r o mO L E T Fr a t sa t3 8w e e k s
of age (Figure 3(b)). When the stainings of SORBS2 and
synaptopodin were merged, they showed as a capillary
pattern in glomeruli from OLETF rats at 38 weeks of age
(Figure 3(c)).
3.5. SORBS2 mRNA Expression in Isolated Glomeruli. To
determine whether SORBS2 localizes within glomeruli and
to assess changes of its expression, real-time Q-PCR analyses
were also performed. Consistent with the QSTAR proteome
analysis results, a tendency towards increased SORBS2Experimental Diabetes Research 5
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Figure 1: Periodic acid Schiﬀ (PAS) and immunohistochemical staining in the kidneys from OLETF (a, c, e, and g) and LETO (b, d, f, and
h) rats at 27 and 38 weeks of age. Slight expansion of the mesangial matrix with mesangial cell proliferation (a). Normal glomeruli (b).
Exudative and sclerotic lesion (c). Normal glomeruli (d). SORBS2 positivity in podocytes from OLETF rats (e, f) and negativity in those
from LETO rats (f, h). Scale bar = 20μm.
mRNA expression in glomeruli from OLETF rats was ob-
served compared to those from LETO rats (1.76±0.15 versus
1.40 ±0.19, P = 0.06).
3.6. Ultrastructural Examination Using Electron Microscopy.
To validate the podocyte foot process eﬀacement in the
OLETF rats, ultrastructural examination was performed at
38 weeks of age. At this time, foot process eﬀacementwas not
observed in the LETO rats, but was obvious in the OLETF
rats (Figures 4(a) and 4(b)). These results and the urinary
protein-to-creatinine ratio (5.65 ± 2.36mg/mg) indicated
that 38 weeks of age is appropriate for the detection of the
proteinuric stage of diabetic nephropathy in the OLETF rats.
4. Discussion
In the present study, we performed a targeted proteome
analysis of glomeruli isolated from rats in both the early (27
weeks of age) and the proteinuric (38 weeks of age) stages of
diabetic nephropathy. It is reported that proteins quantiﬁed
with a fold change of more than 20% (average iTRAQ ratio
>1.20or<0.83)andaP valuelessthan0.05wer eidentiﬁedas
diﬀerentially expressed proteins [26, 27]. We demonstrated
changes of many kinds of proteins in isolated glomeruli
from diabetic rats; these proteins participate in glycolysis,
citric acid cycle, formation of oxidative stress, and other
intracellular processes, as shown in Figure 2. The results
of IPA demonstrated that 17 actin cytoskeleton-associated6 Experimental Diabetes Research
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Figure 2: Comparative analysis of subclasses of diﬀerentially expressed proteins, excluding actin cytoskeleton-associated proteins, in the
kidneys from OLETF and LETO rats at 27 and 38 weeks of age, by the Ingenuity Pathway Analysis (IPA).
proteins were signiﬁcantly and diﬀerentially expressed be-
tween OLETF and LETO rats.
Among these proteins that were diﬀerentially expressed
in isolated glomeruli from OLETF and LETO rats at both
27 and 38 weeks of age were SORBS2 (upregulated),
ARCP1B (downregulated), ARPC5 (downregulated), MAR-
CKS (downregulated), PLAS3 (downregulated), CNN3
(downregulated), and TPM3 (downregulated). SORBS2 was
the only up-regulated protein in glomeruli from OLETF rats
at both the early and the proteinuric stages of diabetic neph-
ropathy,comparedtothosefromLETOrats.Therehavebeen
no previous reports suggesting any relationship between
SROBS2 and diabetic nephropathy.
SORBS2 is an Arg/Abl-binding protein that contains
three COOH-terminal Src homology 3 domains, a serine/
threonine-rich domain, and several potential Abl phospho-
rylation sites. It is widely expressed in human tissues, such
as heart, brain, spleen, pancreas, and kidney. In epithelial
cells, SORBS2 is located in stress ﬁbers [28]. In addition,
SORBS2 has been reported to function as an adapter protein
in the assembly of signaling complexes in stress ﬁbers and
as a potential link between the Abl family kinases and the
actin cytoskeleton [8, 9]. In the present study, SORBS2 was
up-regulated in isolated glomeruli from OLETF rats based
upon proteome analysis using the QSTAR Elite LC-MS/MS.
Although there was a tendency towards increased levels of
SORBS2 mRNA in microdissected glomeruli from OLETF
rats, we conﬁrmed its localization in diabetic glomeruli,
especiallyinpodocytesofOLETFratsattheproteinuricstage
using immunohistochemistry. Considering the previously
reportedfunctionsofSORBS2andthealterationsofSORBS2
expression observed in the present study, SORBS2 may be
associated with the development of diabetic nephropathy by
reorganization of actin ﬁlaments, including actin stress ﬁber
formation.8 Experimental Diabetes Research
20μm
(a)
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(b)
20μm
(c)
Figure 3: Immunoﬂuorescence for SORBS2: red (a), synaptopodin: green (b), and merge SORBS2 and synaptopodin: yellow (c) in OLETF
rats at 38 weeks of age. SORBS2 was expressed as a capillary pattern in glomeruli from OLETF rats at 38 weeks of age. Scale bar = 20μm.
ARCP1B, ARPC5, and MARCKS are actin ﬁlament po-
lymerization-related proteins. During polymerization of
actin ﬁlaments, binding of the Arp2/3 complex to the sides
of actin ﬁlaments is important for its actin nucleation
and branching activities [29]. MARCKS substrate is located
at glomeruli, speciﬁcally to podocytes, and controls both
actin polymerization and actin cytoskeleton binding to the
membrane [30]. Alterations of crosslinking proteins that
organize actin ﬁlaments into bundles or networks, that is,
PLS3 (I-plastin), were also detected in the present study.
PLS3 is an actin-binding protein expressed in the kidney,
that is, known to be located in stress ﬁbers [31] and has
been reported to be related to minimal change nephritic
syndrome [32]. Moreover, CNN3 plays a direct role in cell
contractility in vivo and controls the cytoskeletal composi-
tion of podocytes [33]. TPM3 binds to actin ﬁlaments and
has been implicated in their stabilization [34]. These protein
changes may be related to the collapse of actin ﬁlaments and
the disentanglement of actin bundles or networks of diabetic
glomeruli in the early and proteinuric stages of diabetic
nephropathy.
ACTN4 is widely expressed in podocyte foot processes
and is colocalized with actin stress ﬁbers [6]. The Upregu-
lation of ACTN4 observed during the proteinuric stage in
the present study is consistent with a previous report [10].
ACTN1 is present in multiple subcellular regions, including
cell-cell and cell-matrix contact sites, cellular protrusions,
lamellipodia, and stress ﬁber dense regions [35], and
cross-links actin ﬁlaments within stress ﬁbers [11]. ACTN1
was also up-regulated in glomeruli from OLETF rats at 38
weeks of age. ARHGDIA maintains the Rho family members
(Rac1, Cdc42, and RhoA), which promote the assembly of
actin-myosin ﬁlaments and cell stress ﬁbers in the GDP-
bound inactive form. Mice lacking ARHGDIA are initially
viable and healthy but develop massive proteinuria and
glomerulosclerosis later in life [7, 10]. Upregulation of
ARHGDIA in the early stage might indicate suppression of
the Rho family members. Coincident with the Upregulation
of SORBS2 at both stages of OLETF rats in the present
study, changes in these protein expression patterns may be
associated with reorganization of actin ﬁlaments, leading
to foot process eﬀacement and the progression of diabetic
nephropathy. In the present study; however, we could not
validate the expression of ACTN4 and ARGDIA in OLETF
rats.
In addition to increasing stress ﬁbers, the impairment
of polymerization of actin ﬁlaments, intermediate ﬁlaments
and microtubules, disentanglement of actin ﬁlaments, and
podocyte detachment from the GBM are also key events for
podocytopathies. Intermediate ﬁlaments and microtubules
are known to form the scaﬀold of major podocyte processes
and the central cell body [36]. NES and PLEC1 were down-
regulated in the kidneys from OLETF rats at 27 weeks
of age, indicating the collapse or the disentanglement of
intermediate ﬁlaments and microtubules in the early stage of
diabetic nephropathy. Furthermore, podocytes are attachedExperimental Diabetes Research 9
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Figure 4: Alterations in protein expression during podocyte foot process eﬀacement in diabetic nephropathy. Electron micrograph of
podocytes from OLETF and LETO rats at 38 weeks of age. LETO rats (×40,000) (a), OLETF rats (×40,000) (b).
to the outer aspect of the GBM and their foot processes are
connected to the GBM [37]. Downregulation of INTGB1
and AGR may indicate that podocytes are detached from the
GBM, resulting in foot process eﬀacement and proteinuria.
The alterations of proteins observed in this study are
summarized in Figure 4. Based on proteome analysis of iso-
lated glomeruli from diabetic rats, the following changes of
the cytoskeleton at the early and proteinuric stages of di-
abetic nephropathy could occur: (1) increased formation of
stressﬁbersduringtheproteinuricstageofdiabeticnephrop-
athy, (2) impairment of actin polymerization at both time
points, suggesting collapse or dysfunction of actin ﬁla-
ments, (3) decreased expression of proteins associated with
microtubules and intermediate ﬁlaments during both the
earlyandtheproteinuricstages,(4)decreasedGBMcytoskel-
eton-associated proteins at both stages, suggesting podocy-
topathies, and (5) collapse or disentanglement of actin
ﬁlaments at both stages. Our ﬁndings suggested that impair-
ment or collapse of actin ﬁlaments may cause podocyte
foot process eﬀacement (Figure 4(b)) and the emergence
of proteinuria in diabetic nephropathy. As observed in the
presentstudy,increasesinstressﬁbersattheproteinuricstage
may be related to reorganization of actin ﬁlaments [4, 5].
Proteome analysis demonstrated that numerous cytoskel-
eton-associatedproteinscouldcontributetotheonsetand/or
progression of diabetic nephropathy.
There are some limitations in the present study. First,
in the glomerular isolation, we used a sieving method to
minimize tubular contamination. Despite the implementa-
tion of this technique and eﬀort, it is impossible to com-
pletely avoid tubular contamination. Indeed, one of the
mitochondrial proteins, that is, mitochondrial import inner
membrane translocase subunit 44 (TIM44), which is acti-
vated in diabetic nephropathy [38] was up-regulated in
OLETF rats at 27 weeks of age (fold change 1.34, P =
0.04). A second limitation is the protein detection using
the QSTAR Elite LC-MS/MS. Although, some podocyte-
related proteins, such as podocin and synaptopodin, were
downregulatedinOLETFratsat27weeksofage(foldchange
0.83 P = 0.001; fold change 0.63, P = 0.0001, resp.),
these proteins were not detected in OLETF rats at 38
weeks of age, due to mechanical problems or problems with10 Experimental Diabetes Research
reproducibility of protein identiﬁcation using the QSTAR
EliteLC-MS/MS.Lastly,althoughproteomeanalysisisoneof
the most powerful and useful tools in the detection of novel
proteins for various kidney diseases, it requires validation
or further mechanical analysis of the results of proteome
analysis. Although there are some limitations in the present
methodology, our ﬁndings demonstrated the usefulness of
proteome analysis of isolated glomeruli, which allows the
direct and comprehensive investigation of protein alterations
of diabetic glomeruli.
In conclusion, the present proteome analysis demon-
strated that numerous cytoskeleton-associated proteins con-
tributetotheonsetand/orprogressionofdiabeticnephropa-
thy. This proteome study also demonstrated, for the ﬁrst
time, that SORBS2 expression was increased in diabetic
glomeruliandsuggestedthatSORBS2maybeassociatedwith
the development of diabetic nephropathy by reorganization
of actin ﬁlaments, along with other actin cytoskeleton-asso-
ciatedproteins.Furtherinvestigationisnecessarytoascertain
the signiﬁcance of SORBS2 and these actin cytoskeleton-
associated proteins in diabetic nephropathy.
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